Anti-CD19 chimeric antigen receptor T-cell followed by interferon−α therapy induces durable complete remission in donor cell-derived acute lymphoblastic leukemia: A case report
Donor cell-derived leukemia (DCL) is a special type of relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients with DCL generally have a poor prognosis due to resistance to conventional chemotherapy. Here, we report a case of donor cell-derived acute lymphoblastic leuk...
Main Authors: | Jing Ni, Junjie Zhou, Zhangbiao Long, Xin Chen, Xiaowen Chen, Jian Hong, Xinglin Liang, Qingsheng Li, Ruixiang Xia, Jian Ge |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1021786/full |
Similar Items
-
Improved efficacy with early tocilizumab in the prophylaxis and treatment of cytokine release syndrome of chimeric antigen receptor T cell (CAR-T) therapy for diffuse large B-cell lymphoma than acute lymphoblastic leukemia
by: Chengxin Luan, et al.
Published: (2023-09-01) -
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
by: Li Shiqi, et al.
Published: (2023-06-01) -
Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease
by: Yaya Chu, et al.
Published: (2022-12-01) -
First pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: Long-term remission or early cure?
by: Dimitrios Bouzianas, et al.
Published: (2024-12-01) -
Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission
by: Guan-hua Hu, et al.
Published: (2022-01-01)